NCT07040813View on ClinicalTrials.gov

The Nordic Chronic Migraine Trial of CGRP Monoclonal Antibody and Onabotulinumtoxin A Dual Therapy Compared to CGRP mAbs Monotherapy

PHASE3RecruitingINTERVENTIONAL
Enrollment

450

Participants

Timeline

Start Date

June 6, 2025

Primary Completion Date

January 31, 2029

Study Completion Date

April 30, 2029

Conditions
MigraineChronic Migraine Headache
Interventions
DRUG

CGRP mAbs and onabotulinumtoxin A

CGRP mAbs given subcutanously every 4th week and onabotulinumtoxin A 155 given once intramuscularly according to adjusted PREEMPT protocol in the 12 week period of study intervention.

DRUG

CGRP mAbs and placebo

CGRP mAbs given subcutanously every 4th week and placebo once intramuscularly according to adjusted PREEMPT protocol in the 12 week period of study

Trial Locations (6)

Unknown

NOT_YET_RECRUITING

Østfold Hospital Trust, Grålum

NOT_YET_RECRUITING

Sørlandet Hospital Kristiansand, Kristiansand

NOT_YET_RECRUITING

Innlandet Hospital Trust Lillehammer, Lillehammer

NOT_YET_RECRUITING

Telemark Hospital Trust Skien, Skien

NOT_YET_RECRUITING

St. Olav University Hospital, Trondheim

0424

RECRUITING

Oslo University Hospital, Oslo

All Listed Sponsors
collaborator

St. Olavs Hospital

OTHER

collaborator

Sykehuset Telemark

OTHER_GOV

collaborator

Sykehuset Innlandet HF

OTHER

collaborator

Sorlandet Hospital HF

OTHER_GOV

collaborator

Ostfold Hospital Trust

OTHER

lead

Oslo University Hospital

OTHER